Brett Staahl and Benjamin Oakes
October 6, 2020 10:38 AM EDTUpdated October 8, 04:05 PM
People
Startups

The lat­est Jen­nifer Doud­na start­up launch­es with a Bio­gen part­ner­ship and eyes on big tar­gets few CRISPR com­pa­nies have chased

Jason Mast

Editor

Three years ago, Jen­nifer Doud­na gath­ered with two post­docs and a fel­low bio­chemist around a cir­cu­lar ta­ble on the sec­ond floor of UC Berke­ly’s En­er­gy …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times